References
- JännePAOuSHKimDWDacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trialLancet Oncol201415131433144125456362
- WuYLLuSChengYEfficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancerLung Cancer201485340140725082564
- SteedEElbediwyAVaccaBMarvelD3 couples tight junctions to the MEKK1-JNK pathway to regulate cell behavior and survivalJ Cell Biol2014204582183824567356
- HarrellJCPfefferleADZallesNEndothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasisClin Exp Metastasis2014311334523975155
- PhilipRHeilerSMuWBüchlerMWZöllerMThumaFClaudin-7 promotes the epithelial-mesenchymal transition in human colorectal cancerOncotarget2015642046206325514462
- AgarwalRMoriYChengYSilencing of claudin-11 is associated with increased invasiveness of gastric cancer cellsPLoS One2009411e800219956721
- JakabCSRusvaiMDemeterZGálfiPSzabóZKulkaJExpression of claudin-4 molecule in canine exocrine pancreatic acinar cell carcinomasHistol Histopathol20112691121112621751143
- HuangGWDingXChenSLZengLExpression of claudin 10 protein in hepatocellular carcinoma: impact on survivalJ Cancer Res Clin Oncol201113781213121821647678
- CoyneCBBergelsonJMVirus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctionsCell2006124111913116413486
- SchneebergerEELynchRDThe tight junction: a multifunctional complexAm J Physiol Cell Physiol20042866C1213C122815151915
- EvansMJvon HahnTTscherneDMClaudin-1 is a hepatitis C virus co-receptor required for a late step in entryNature2007446713780180517325668
- NagaseSDoyamaRYagiKKondohMRecent advances in claudin-targeting technologyBiol Pharm Bull201336570871423649330
- KotlerBMKerstetterJEInsognaKLClaudins, dietary milk proteins, and intestinal barrier regulationNutr Rev2013711606523282252
- SabatierRFinettiPGuilleAClaudin-low breast cancers: clinical, pathological, molecular and prognostic characterizationMol Cancer20141322825277734
- IzraelySSagi-AssifOKleinAThe metastatic microenvironment: claudin-1 suppresses the malignant phenotype of melanoma brain metastasisInt J Cancer201513661296130725046141
- SungCOHanSYKimSHLow expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinomaAnn Surg Oncol201118127328120839069
- WangLJinXLinDClinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases-2 expression in ovarian carcinomaDiagn Pathol2013819024245968
- UshikuTShinozaki-UshikuAMaedaDMoritaSFukayamaMDistinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomasHistopathology20126161043105622803571
- WuQLiuYRenYTight junction protein, claudin-6, downregulates the malignant phenotype of breast carcinomaEur J Cancer Prev201019318619420215972
- BirksDKKleinschmidt-DeMastersBKDonsonAMClaudin 6 is a positive marker for atypical teratoid/rhabdoid tumorsBrain Pathol201020114015019220299
- MickePMattssonJSEdlundKAberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancerInt J Cancer201413592206221424710653